Immunology and Microbiology
T Cell
100%
CD8
31%
Cytotoxic T-Cell
30%
Tumor-Infiltrating Lymphocytes
28%
CD20
28%
Antineoplastic Activity
23%
T Cell Receptor
23%
Lymphocyte
23%
Bispecific Antibody
23%
Monospecific Antibody
23%
CXCL13
23%
Tumor Cell
23%
Epidermal Growth Factor
23%
Immunity
23%
Cytotoxicity
21%
Atezolizumab
15%
Co-Stimulation
15%
Cetuximab
15%
Cancer Cell
10%
Natural Killer Cell
9%
Tumor Immunity
9%
Tumor Antigen
9%
RNA Sequence
8%
Programmed Death 1 Ligand 1
7%
Gamma Urogastrone
7%
Tumor-Associated Macrophage
7%
Cross Linking
7%
Scanning Electron Microscopy
7%
Biological Activity
7%
Growth Inhibition
7%
Adoptive Immunity
7%
Immune Checkpoint Blockade
5%
Immune System
5%
Ovary
5%
Survival Rate
5%
Immunomodulatory Drug
5%
Cancer Immunotherapy
5%
Immunotherapy
5%
Medicine and Dentistry
Krukenberg Tumor
49%
T Cell
43%
Neoplasm
38%
Tumor Infiltrating Lymphocyte
36%
Malignant Neoplasm
30%
CD8 Antigen
26%
Ovarian Cancer
24%
T Lymphocyte Receptor
23%
Epidermal Growth Factor Receptor
23%
Antineoplastic Activity
23%
G Protein Coupled Receptor
23%
Bispecific Antibody
23%
Lymphocyte
23%
Cancer Therapy
23%
Immunity
23%
Co-Stimulation
15%
Cytotoxicity
10%
Biological Marker
9%
Immune Checkpoint Inhibitor
9%
Tumor Antigen
9%
Cancer
9%
Receptor
9%
Cancer Cell
9%
Tumor Immunity
7%
Cross-Link
7%
Cancer Types
6%
Fatality
5%
Disease
5%
Immunosuppressive Treatment
5%
Nanoparticle
5%
Immune System
5%
Immunotherapy
5%
Polysaccharide
5%
CD20
5%
Five-Year Survival Rate
5%
Cancer Immunotherapy
5%
Targeted Therapy
5%
Immunomodulatory Drug
5%
Cytotoxic T-Cell
5%
Tumor Microenvironment
5%
Cellular Immunity
5%
T Lymphocyte
5%
Keyphrases
Targeted Delivery
23%
G Protein-coupled Receptor 56
23%
Functionalization of Polysaccharides
23%
Carbonate Nanoparticles
23%
Epithelial Ovarian Cancer
23%
Delivery Strategy
23%
Immune Checkpoint
23%
Ovarian Cancer Screening
23%
Polysaccharide Nanoparticles
13%
Ovarian Cancer
11%
Dissipation Monitoring
7%
D-flow
7%
Tumor-infiltrating Lymphocytes
5%
Prognosis Treatment
5%
GPR56
5%
Advanced Stage
5%
Targeted Treatment
5%
Drug Delivery Strategies
5%
Limited Treatment Options
5%
5-year Survival
5%
Off-target Toxicity
5%
Immune Checkpoint Inhibitors
5%
Gynecologic Malignancies
5%
Immune System
5%
Tim-3
5%
Immune Suppression
5%
Tumor Antigen
5%
Immunomodulatory Drugs (IMiDs)
5%
Cancer Immunotherapy
5%
Treatment Landscape
5%
Healthy Tissue
5%
Targeted Drug Delivery
5%
Novel Therapeutics
5%
Evade
5%
Poor Prognosis
5%
CD20
5%
Relevant Subset
5%
Delivery Vehicle
5%
Advanced Ovarian Cancer
5%
Novel Types
5%
Fatality
5%
